Navigation Links
KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent
Date:12/15/2009

rward-looking statements and related assumptions.

Such factors include (but are not limited to) the following:

  1. the ability to continue as a going concern;
  2. the consent decree between the Company and the U.S. Food and Drug Administration (the "FDA") and the Company's suspension of the production and shipment of all of the products that the Company manufactures and the related nationwide recall affecting all of the products that the Company manufactures, as well as the related material adverse effect on the Company's revenue, assets and liquidity and capital resources, all as more fully described in the Company's Form 8-K filed with the SEC on January 26, 2009, the Company's Form 8-K filed with the SEC on February 26, 2009, the Company's Form 8-K filed with the SEC on March 3, 2009, the Company's Form 8-K filed with the SEC on April 30, 2009, the Company's Form 8-K filed with the SEC on July 24, 2009 and the Company's Form 8-K filed with the SEC on November 12, 2009;
  3. the degree to which the findings of the Audit Committee inquiry referenced in the Company's Form 10-Q for the quarter ended June 30, 2008, the Company's Form 12b-25 filed with the SEC on November 13, 2008, the Company's Form 12b-25 filed with the SEC on February 2, 2009, the Company's Form 12b-25 filed with the SEC on June 6, 2009, the Company's Form 8-K filed with the SEC on June 23, 2009, the Company's two Form 12b-25s filed with the SEC on November 10, 2009, as well as certain other of the Company's SEC filings, could have a material impact on the Company's financial results;
  4. changes in the current and future business environment, including interest rates and capital and consumer spending;
  5. the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized;
  6. the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals;
  7. acceptance of and demand for the Company's ne
    '/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital
2. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
3. Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
4. GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms
5. New Report Grades Sustainability Reporting of Top Pharmaceutical Companies
6. Ohr Pharmaceutical Selects Allen & Caron for Investor Relations, Corporate Communications
7. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
8. Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
9. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
10. New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies
11. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... Laboratories, will move its laboratory operations in ... Raleigh Durham , North Carolina.  Sequenom ... performed at the North Carolina ...
(Date:5/27/2015)... , May 27, 2015 OpportunityAnalyzer: ... 2018 Summary GlobalData estimates that the ... market was approximately $179m across the 6MM covered ... are investing their attention, time, and financial resources ... of research and development (R&D) strategies. One notable ...
(Date:5/27/2015)... , May 27, 2015 Protein purification involves ... on differences in their physical properties. The objective of ... amount of functional protein with fewest contaminants. The global ... at a CAGR of around 5% to 6% during ... increased research in the pharmaceutical and biotechnological fields, growing ...
Breaking Medicine Technology:Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 2Sequenom Laboratories To Consolidate Michigan And North Carolina Facilities 3OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 2OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 3OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018 4Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 2Protein Purification & Isolation Market by Technology by Product by Application & End User - Global Forecast to 2020 3
... Phase III Study Provides Further Evidence of,the ... the Treatment,of Rheumatoid Arthritis, BASEL, Switzerland, June ... second multinational phase III Actemra,(tocilizumab) study, successfully ... greater proportion of patients treated with Actemra,in ...
... Production Through Inhibition,of PDE-4 Enzyme, PALO ALTO, ... a privately held pharmaceutical company, announced,today the ... of,AN2728, a first-in-class topical therapy under investigation ... AN2728 to be,well-tolerated, with activity comparable to ...
Cached Medicine Technology:New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 2New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 3New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 4Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2
(Date:5/28/2015)... Portland, Ore. (PRWEB) May 28, 2015 ... announced today that it has been named a “Cool ... titled Cool Vendors in Healthcare Payers, 2015 ... J. Lheureux. The report highlights innovative vendors, products and ... into new trends in the health care payer market. ...
(Date:5/28/2015)... Atlanta, GA (PRWEB) May 28, 2015 ... it will be breaking ground this summer on an ... , Focusing on resident engagement and connectivity in a ... a blend of innovative technology and southern hospitality to ... seniors. , The 93 unit community will feature luxuriously ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 JJ Mowder-Tinney, PT, ... of the New York Physical Therapy Association (NYPTA) by the ... an active member of the NYPTA. At the National ... the Neurology Section Research Committee and an abstract reviewer for ... she has been a member of the Program committee since ...
(Date:5/27/2015)... Gravity and volume loss in the ... Management Expert™, Holly CaSaroll, is excited to introduce a ... the mid face, without surgical intervention, and without downtime. ... a FDA approved procedure that can lift skin using ... is a new more lifting formula than its predecessor ...
(Date:5/27/2015)... 28, 2015 Calls Upon Individuals, Organizations and ... new nationwide initiative – a “Summer of Service” – seeks ... build partnerships to grow the number of individuals and organizations ... commitment to Veterans by inviting the community to visit and ... 29, 2015 from 1 – 3:00 p.m. in the auditorium. ...
Breaking Medicine News(10 mins):Health News:SpendWell Named a “Cool Vendor” by Gartner 2Health News:SpendWell Named a “Cool Vendor” by Gartner 3Health News:SpendWell Named a “Cool Vendor” by Gartner 4Health News:Thrive Announces Innovative New Senior Living Community in Huntsville, AL 2Health News:Skin Expert Holly CaSaroll Announces New Cutting Edge Results with RadiessePlus Filler Available at Detroit Skin and Wellness Clinic 2Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 2Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 3
... disorder is a serious and debilitating condition where individuals ... The episodes of low or elevated mood can last ... high. Antidepressants are commonly prescribed to ... not universally effective. Many patients still continue to experience ...
... , WEDNESDAY, May 30 (HealthDay News) -- ,The ancient medical ... a small new study suggests. Metabolic syndrome is a ... type of fat found in the blood), high fasting blood ... risk of diabetes and heart disease. Bloodletting was common ...
... information women receive about their future fertility following cancer diagnosis, ... BJOG: An International Journal of Obstetrics and Gynaecology . ... are increasing numbers of people of reproductive age undergoing such ... of Aberdeen and NHS Grampian - looks at perceptions and ...
... (HealthDay News) -- A popular European fitness routine called Nordic ... a small new study. In Nordic walking, people walk ... those in cross-country skiing. This fast-growing form of exercise in ... heart failure patients, quality of life and reduces their risk ...
... , TUESDAY, May 29 (HealthDay News) -- ,Adult survivors ... quality of life because of the long-term physical effects ... Researchers used data from the Childhood Cancer Survivor Study ... hair loss experienced by more than 14,000 adult survivors ...
... , TUESDAY, May 29 (HealthDay News) -- Healthy brain nerve ... intelligence later in life, according to a new study. ... older people with robust brain wiring (white matter, or nerve ... a sign of intelligence. The study of 420 people ...
Cached Medicine News:Health News:Ketamine improved bipolar depression within minutes 2Health News:Could Bloodletting Ease Heart Risks for the Obese? 2Health News:Men and women receive different fertility advice following cancer diagnosis 2Health News:Men and women receive different fertility advice following cancer diagnosis 3Health News:'Nordic Walking' a Winner for Heart Failure Patients, Study Says 2Health News:Emotional Woes May Last for Childhood Cancer Survivors 2Health News:Healthy Brain Connections Help Maintain Intellect in Old Age 2
Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g. Overall length 16 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Retrobulbar Needle, 23 g. Atkinson style bevel. Overall length 38 mm. 5/box....
20 g MVR knife. Dimensions: 31.8 mm x 1.18 mm x 2.7 mm....
Medicine Products: